Background
A major life sciences company required Ayesda Bio to deliver a new wave of their established global buying preferences tracker. The study needed to cover three diverse markets — the USA, China, and Germany — with strict quota requirements and full consistency with previous waves to maintain the integrity of long-term trend data.
Tracker studies carry unique pressures: any deviation in sample quality, respondent profile, or methodology can compromise the longitudinal value of the entire dataset.
Our Approach
Ayesda Bio managed end-to-end fieldwork across all three markets, recruiting life sciences professionals who met precise quota criteria for role, seniority, therapeutic area focus, and purchasing responsibility. Our network provided direct access to verified respondents without reliance on third-party routing or aggregated sample.
Rigorous quality controls were applied throughout — including screening validation, response time monitoring, and consistency checks against prior wave benchmarks. Our multilingual team coordinated across time zones to ensure fieldwork ran to schedule.
Outcome
All 200 interviews were completed on schedule and to specification, maintaining full continuity with previous waves. The client received clean, validated data that integrated seamlessly with their existing longitudinal dataset, enabling robust trend analysis across markets.
Data quality metrics — including completion rates, open-end quality, and respondent engagement scores — exceeded the client's benchmarks for this wave.
Key takeaway: Tracker studies live or die on consistency. Our direct-access network and rigorous quality protocols ensured this wave matched the standards set in previous rounds — protecting the long-term value of the client's investment.